期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP3A5基因多态性与肿瘤耐药和治疗的相关性研究现状 被引量：2

原文传递
导出
摘要 目的:本文通过整理分析有关CYP3A5的研究成果,对CYP3A5作综述分析,为临床联合用药的选择和个体化治疗提供参考及理论基础。方法:从CYP3A5基因的多态性、CYP3A5与肿瘤耐药和治疗的相关性等方面阐述该酶的多态性研究现状和肿瘤耐药机制。结果:CYP3A5是CYP3A亚家族最主要的肝外分布形式,其底物众多,基因多态性复杂,变异性强,个体差异大,在药物的相互作用中发挥至关重要的作用,并与肿瘤化疗耐药密切相关。结论:用药前的基因检测将成为临床个体化治疗的趋势;进口药于我国上市前应进行以中国人为对象的临床试验;导入基因以降低肿瘤耐药的治疗方案将继续被关注。
作者 刘恩溢 李玉珍 方翼
机构地区 北京大学医学部 北京大学人民医院药剂科
出处 《中国药房》 CAS CSCD 北大核心 2011年第42期4002-4005,共4页 China Pharmacy
关键词 CYP3A5 多态性 细胞色素P450 个体化治疗 基因 肿瘤 耐药
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献3

二级参考文献33

  • 1张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石.细胞色素P450 3A5和多药耐药基因1基因多态性在肾移植患者他克莫司血药浓度监测中的应用[J].肾脏病与透析肾移植杂志,2004,13(4):313-317. 被引量：21
  • 2王汉平,毛平,谢健晋,许艳丽,莫文健,杜庆华,朱志刚.细胞色素P-450 3A5基因类型影响造血干细胞移植患者血环孢素浓度[J].中华器官移植杂志,2005,26(4):207-209. 被引量：5
  • 3Shankar P,Manjunath N,Lieberman J.The prospect of silencing disease using RNA interference.JAMA,2005,293(11):1367-1373.
  • 4Zhou Q,Yao TW,Yu YN,et al.Stereoselective metabolism of propafenone by human liver CYP3A4 expressed in transgenic Chinese hamster CHL cells lines.Acta Pharmacol Sin,2001,22(10):944-998.
  • 5Hariparsad N,Sane RS,Strom SC,et al.In vitro methods in human drug biotransformation research:implications for cancer chemotherapy.Toxicol in Vitro,2006,20(2):135-153.
  • 6Lu AY,Wang RW,Lin JH.Cytochrome P450 in vitro reaction phemotyping:a revaluation of approaches used for P450 isoform identification.Drug Metab Dispos,2003,31(4):345-350.
  • 7Thompson JD.Applications of antisense and siRNAs during preclinical drug development.Drug Discov Today,2002,7(17):912-917.
  • 8Ophelia,Shi X.J, Tomlinson B, et al. Interindividual and Intraindividual Variability of the Urinary 6β-hydroxycortisol/cortisol Ratio in Chinese Subjects:Implications of Its Use for Evaluating CYP3A Activity [J]. Journal of Clinical Pharmacology, 2004,44:1412-1417
  • 9Jens Lykkesfeldt,Steffen Loft,Henrik E. Stimultaneous determination of urinary free cortisol and high-performance liquid chromatography to measure human CYP3 A activity [J]. Journal of Chromatography 8, 1994 (660) :23-29
  • 10Leeder JS. Developmental and pediatric pharmacogenomics [J]. Pharmacogenomics ,2003,4(3 ) :331-337

共引文献14

同被引文献70

  • 1Dong N,Yu J, Wang C,et al. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer trea- ted with docetaxel plus capecitabine [ J ]. J Cancer Res Clin Onco1,2012,138 (7) : 1197-1203.
  • 2Van Erp NP, Eechoute K,van der Veldt AA,et al. Pharmaco- genetic pathway analysis for determination of sunitinib-in-duced toxicity[J]. J Clin 0ncot,2009,27(26) :4406-4412.
  • 3Nie Q,Yang XN,An SJ,et al. CYP1A1 *2A polymorphism as a predictor of clinical outcome in advanced lung cancer pa- tients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism [ J ]. Eur J Cancer, 2011,47 (13) : 1962-1970.
  • 4Laroche-Clary A, Le Morvan V, Yamori T, et al. Cytochrome P450 1 B1 gene polymorphisms as predictors of anticancer drug activity: sudies with in vitro models [ J ]. Mol Cancer Ther', 2010,9(12) :3315-3321.
  • 5Pastira I, Giovannetti E ,Chioni A ,et al. Cytochrome 450 1 B1 (CYP1B1) potymorphisms associated with response to do- cetaxel in Castration-Resistant Prostate Cancer (CRPC) pa- tients [ J ]. BMC Cancer,2010,10:511.
  • 6Rizza R,-Spaggiari F,hadelli M,et al. Association of CYP1B1 with hypersensitivity iodueed by taxane therapy in breast eancer patients [ J ]. Breast Cancer Res Treat, 2010,124 ( 2 ) : 593-598.
  • 7Park SR,Kong SY,Nam BH,et al. CYP2A6 and ERCC1 pol- ymorphisms correlate with efficacy of S-! plus eisplatin in me- tastatic gastric cancer patients [ J] . Br J Cancer, 2011,104 (7) :1126-1134.
  • 8Kong SY, Lira HS, Nam BH, et al. Association of CYP2A6 polymorphisms with S-1 plus dQcetaxel therapy outcomes in metastatic gastric cancer [ J ]. Pharmacogenomics, 2009, 10 (7) :1147-1155.
  • 9Xie HJ, Yasar U, Lundgren S, et al. Role of polymorp!aic hu- man CYP2B6 in cyclophosphamide bioactivation [ J ]. Phar- rnacogenomies , 2003,3:53-61.
  • 10Xie HJ, Griskevicius L, Stgthle L, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies [ J ]. Eur J Pharm Sci, 2006,27 : 54-61.

引证文献2

二级引证文献22

中国药房
2011年 第42期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部